Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma

Arthritis and Rheumatology

Volumn 67, Issue 4, 2015, Pages 1053-1061

  Shah, Ami A ^a   Hummers, Laura K ^a   Casciola Rosen, Livia ^a   Visvanathan, Kala ^a   Rosen, Antony ^a   Wigley, Fredrick M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE III; DNA DIRECTED RNA POLYMERASE III ANTIBODY; DNA TOPOISOMERASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CAUCASIAN; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; ECHOCARDIOGRAPHY; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SKIN CANCER; AGED; BLOOD; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; NEOPLASM; RISK FACTOR; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 84925832832     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39022     Document Type: Article

References (20)

1. Olesen AB, Svaerke C, Farkas DK, Sorensen HT,. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010; 163: 800-6.
2. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G,. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 2001; 134: 1087-95.
3. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100.
4. Zantos D, Zhang Y, Felson D,. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994; 21: 1855-9.
5. Launay D, Le Berre R, Hatron PY, Peyrat JP, Hachulla E, Devulder B, et al. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004; 23: 516-22.
6. Lu TY, Hill CL, Pontifex EK, Roberts-Thomson PJ,. Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study. Rheumatol Int 2008; 28: 895-9.
7. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L,. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010; 62: 2787-95.
8. Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F,. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011; 38: 1329-34.
9. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13: R211.
10. Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014; 16: R53.
11. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014; 343: 152-7.
12. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
13. Steen VD,. The many faces of scleroderma. Rheum Dis Clin North Am 2008; 34: 1-15, v.
14. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
15. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-87.
16. Knudson RJ, Kaltenborn WT, Knudson DE, Burrows B,. The single-breath carbon monoxide diffusing capacity: reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis 1987; 135: 805-11.
17. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461-6.
18. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
19. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65: 2954-62.
20. Shah AA, Rosen A,. Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 2011; 23: 530-5.